Hetlioz for Non-24-Hour Disorder Now Available
Vanda Pharmaceuticals Inc this week announced the availability of Hetlioz. Hetlioz is the first treatment approved by the US Food and Drug Administration (FDA) for Non-24-Hour Sleep-Wake Disorder (Non-24), a chronic circadian rhythm disorder that affects up to 70% of people who are totally blind.
Vanda has launched HetliozSolutions to support and facilitate the treatment of totally blind people living with Non-24. HetliozSolutions will provide patients with a host of resources including information about Non-24 and Hetlioz, insurance support, overview of financial assistance programs, and pharmacy access.
“The availability of Hetlioz marks a major milestone for totally blind people who have been without an approved, safe, and effective treatment for Non-24. We are also excited to bring a broad range of services to patients through HetliozSolutions,” says Mihael H. Polymeropoulos, MD, Vanda’s president and CEO, in a release.
Hetlioz, which was approved by the FDA in January 2014, is available through specialty pharmacies in the United States.